Clinical Trial

Study of HLD-0915 in Patients With Metastatic Prostate Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Assessment of the safety and efficacy of HLD-0915 in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Protocol Amendment History 1 change
notable Sponsor changed: Halda Therapeutics OpCo, Inc. -> Janssen Research & Development, LLC 2026-07-26
Trial Details
NCT Number NCT06800313
Lead Sponsor Halda Therapeutics OpCo, Inc.
Conditions Metastatic Prostate Cancer
Enrollment 190 participants
Start Date 2025-02-20
Primary Completion 2028-04 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-26